The blockade of adhesion of CML-initiating cells to E-selectin expressed on the bone marrow endothelium increased cell cycle progression and the SCL/TAL1 signaling axis in leukemia cells, improving the efficacy of imatinib treatment [52]. This evidence concerns the gene TAL1 and chronic myelogenous leukemia, BCR-ABL1 positive.